SWOG Cancer Research Network study S2207 is enrolling patients with relapsed, refractory large B-cell lymphoma
Tricia Hernandez, Director of Community Engagement at The Leukemia and Lymphoma Society, shared a post by SWOG Cancer Research Network, on LinkedIn:
“Honored to serve as the SWOG Cancer Research Network Lymphoma research advocate and see the relentless pursuit of more durable, less toxic treatments for patients most in need!”
Quoting SWOG Cancer Research Network‘s Post:
“SWOG Cancer Research Network study S2207 is enrolling patients with relapsed, refractory large B-cell lymphoma.
3-arm trial adds tazemetostat or zanubrutinib to tafasitamab-lenalidomide.
PI: Jennifer Amengual, MD Columbia University Irving Medical Center.”
Tricia Hernandez is the Director of Community Engagement at The Leukemia and Lymphoma Society, where she has implemented initiatives to enhance online community support for patients, caregivers, and healthcare professionals. Tricia has led national adolescent and young adult (AYA) support efforts, including establishing an AYA Advisory Group, creating an outreach guide, and coordinating content for a national magazine. Previously, she served as Co-Executive Director at Spectrum Community Services.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023